Analysts Offer Predictions for Nephros Q2 Earnings

Nephros Inc. (NASDAQ:NEPH) – Northland Securities issued their Q2 2026 earnings per share (EPS) estimates for Nephros in a report released on Friday, July 17th. Northland Securities analyst B. Brooks anticipates that the company will post earnings of $0.01 per share for the quarter. Northland Securities currently has a “Market Perform” rating and a $4.00 price target on the stock. Northland Securities also issued estimates for Nephros’ Q3 2026 earnings at $0.01 EPS, Q4 2026 earnings at $0.00 EPS, FY2026 earnings at $0.03 EPS, Q1 2027 earnings at $0.03 EPS, Q2 2027 earnings at $0.05 EPS, Q3 2027 earnings at $0.06 EPS, Q4 2027 earnings at $0.06 EPS and FY2027 earnings at $0.19 EPS.

Nephros (NASDAQ:NEPH) last issued its earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.01. The company had revenue of $5.21 million for the quarter, compared to analysts’ expectations of $5.02 million. Nephros had a net margin of 4.06% and a return on equity of 7.66%.

Separately, Weiss Ratings downgraded shares of Nephros from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday. One research analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $5.00.

Nephros Stock Performance

NASDAQ:NEPH opened at $3.68 on Tuesday. The firm has a 50-day simple moving average of $3.46 and a 200-day simple moving average of $3.64. Nephros has a one year low of $2.66 and a one year high of $6.42. The firm has a market cap of $39.96 million, a P/E ratio of 52.58 and a beta of 1.49.

Institutional Investors Weigh In On Nephros

Institutional investors have recently added to or reduced their stakes in the stock. Kestra Advisory Services LLC purchased a new position in Nephros in the fourth quarter valued at about $29,000. Dimensional Fund Advisors LP lifted its position in shares of Nephros by 52.5% during the first quarter. Dimensional Fund Advisors LP now owns 20,745 shares of the company’s stock valued at $62,000 after buying an additional 7,144 shares during the last quarter. Heron Bay Capital Management bought a new stake in shares of Nephros in the 4th quarter valued at about $66,000. Citadel Advisors LLC boosted its holdings in shares of Nephros by 39.2% in the 3rd quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock valued at $78,000 after buying an additional 4,655 shares in the last quarter. Finally, XTX Topco Ltd grew its position in shares of Nephros by 48.5% in the 4th quarter. XTX Topco Ltd now owns 21,617 shares of the company’s stock worth $105,000 after buying an additional 7,062 shares during the last quarter. Institutional investors own 41.10% of the company’s stock.

Key Stories Impacting Nephros

Here are the key news stories impacting Nephros this week:

• Positive Sentiment: Nephros announced it will participate in Maxim Group’s “Health, Wellness & Longevity” virtual conference on July 22, which could increase investor attention and highlight the company’s story. Article Title
• Neutral Sentiment: Northland Securities reiterated a Market Perform rating and $4.00 price target on Nephros, with estimates pointing to gradual earnings growth through 2026 and 2027, including FY2026 EPS of $0.03 and FY2027 EPS of $0.19. The update is supportive, but the neutral rating suggests analysts are not calling for a major revaluation yet.

Nephros Company Profile

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.